Anna Prats-Puig1, Pilar Soriano-Rodríguez2, Gemma Carreras-Badosa1, Elena Riera-Pérez3, Monserrat Ros-Miquel4, Antoni Gomila-Borja4, Francis de Zegher5, Lourdes Ibáñez6, Judit Bassols1, Abel López-Bermejo7. 1. 1] Pediatrics Research Group, Girona Institute for Biomedical Research, Girona, Spain [2] Department of Pediatrics, Dr Josep Trueta Hospital, Girona, Spain. 2. Clinical Laboratory Salut Empordà Foundation, Figueres, Spain. 3. Department of Pediatrics, Salut Empordà Foundation, Figueres, Spain. 4. Department of Pediatric Surgery, Dr Josep Trueta Hospital, Girona, Spain. 5. Department of Development & Regeneration, University of Leuven, Leuven, Belgium. 6. 1] Department of Pediatric Endocrinology, Sant Joan de Déu Children's Hospital, Esplugues, Barcelona, Spain [2] CIBERDEM (Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders), Instituto de Salud Carlos III, Madrid, Spain. 7. 1] Pediatrics Research Group, Girona Institute for Biomedical Research, Girona, Spain [2] Department of Pediatrics, Dr Josep Trueta Hospital, Girona, Spain [3] TransLab Research Group, Department of Medical Sciences, Faculty of Medicine, University of Girona, Girona, Spain.
Abstract
BACKGROUND: Secreted frizzled-related protein 5 (SFRP5) is an adipokine protecting against obesity-related insulin resistance and diabetes. SFRP5 binds to wingless type mouse mammary tumor virus (MMTV) integration site family member 5A (WNT5A) to improve insulin sensitivity. We performed the first study of SFRP5 and WNT5A simultaneously in children. METHODS: Prepubertal children (n = 342) were assessed for circulating SFRP5 (all subjects) and circulating WNT5A (210 subjects), and associations were sought with metabolic markers. In conditioned media of adipose tissue explants from 12 additional children, SFRP5 and WNT5A were studied further. RESULTS: The concentrations of SFRP5 and WNT5A correlated positively in serum and in conditioned media (all P < 0.001). Lower level of circulating SFRP5 (lowest quartile) was associated with higher BMI (15% increase, P < 0.0001) and lower level of high-molecular-weight adiponectin (26% decrease, P = 0.002). Circulating WNT5A related closely with insulin resistance assessed by the homeostasis model assessment for insulin resistance and hepatic markers (alanine transaminase and gamma glutamyl transpeptidase), particularly in children with lower circulating SFRP5 levels (all P < 0.004). CONCLUSION: SFRP5 and WNT5A comprise a balanced duo that may regulate metabolic homeostasis in prepubertal children.
BACKGROUND:Secreted frizzled-related protein 5 (SFRP5) is an adipokine protecting against obesity-related insulin resistance and diabetes. SFRP5 binds to wingless type mouse mammary tumor virus (MMTV) integration site family member 5A (WNT5A) to improve insulin sensitivity. We performed the first study of SFRP5 and WNT5A simultaneously in children. METHODS: Prepubertal children (n = 342) were assessed for circulating SFRP5 (all subjects) and circulating WNT5A (210 subjects), and associations were sought with metabolic markers. In conditioned media of adipose tissue explants from 12 additional children, SFRP5 and WNT5A were studied further. RESULTS: The concentrations of SFRP5 and WNT5A correlated positively in serum and in conditioned media (all P < 0.001). Lower level of circulating SFRP5 (lowest quartile) was associated with higher BMI (15% increase, P < 0.0001) and lower level of high-molecular-weight adiponectin (26% decrease, P = 0.002). Circulating WNT5A related closely with insulin resistance assessed by the homeostasis model assessment for insulin resistance and hepatic markers (alanine transaminase and gamma glutamyl transpeptidase), particularly in children with lower circulating SFRP5 levels (all P < 0.004). CONCLUSION:SFRP5 and WNT5A comprise a balanced duo that may regulate metabolic homeostasis in prepubertal children.
Authors: S Porro; V A Genchi; A Cignarelli; A Natalicchio; L Laviola; F Giorgino; S Perrini Journal: J Endocrinol Invest Date: 2020-11-03 Impact factor: 4.256
Authors: José J Fuster; María A Zuriaga; Doan Thi-Minh Ngo; Melissa G Farb; Tamar Aprahamian; Terry P Yamaguchi; Noyan Gokce; Kenneth Walsh Journal: Diabetes Date: 2014-10-28 Impact factor: 9.461
Authors: Laia Bertran; Marta Portillo-Carrasquer; Andrea Barrientos-Riosalido; Carmen Aguilar; David Riesco; Salomé Martínez; Amada Culebradas; Margarita Vives; Fàtima Sabench; Daniel Del Castillo; Cristóbal Richart; Teresa Auguet Journal: Int J Mol Sci Date: 2022-08-30 Impact factor: 6.208